







INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10228B				SERIAL NO. Express Mail Label No. EL446402284US						
		APPLICANT Farzan Rastinejad et al.				09/863 976						
		FILING DATE May 23, 2001				GROUP 1624						
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS												
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
												YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
2			G. Selivanova, et al., <i>Nature Medicine</i> ; 3, pp. 632-638, 1997									
2			R. K. Brachmann, et al., <i>The EMBO Journal</i> ; 17, pp.1847-1859, 1998									
2			P. V. Nikolova, et al., <i>Proceedings of the National Academy of Science, USA</i> ; 95, pp. 14675-14680, 1998									
2			Ted R. Hupp, et al., <i>Cell</i> ; Vol. 83, pp.237-245, 1995									
2			B. A. Foster, et al., <i>Science</i> ; Vol. 286, pp. 2507-2510, 1999									
2			Rebecca L. Rawls, <i>Chemical and Engineering News</i> ; pp. 38-41, issue of February 17, 1997									
2			Alex N. Bullock, et al., <i>Oncogene</i> ; 19, pp. 1245-1256, 2000									
2			Yunje Cho, et al., <i>Science</i> , 265, pp. 346-355, 1994									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
EXAMINER		DATE CONSIDERED						9/17/02				


2

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>								ATTY. DOCKET NO. PC10228B				SERIAL NO. Express Mail No. EL446402284US							
								APPLICANT Farzan Rastinejad et al.								09/863,976			
								FILING DATE May 23, 2001								GROUP 1624 (anticipated)			
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
													YES	NO					
2		WO	94/	1	2	2	0	2	6/9/94	PCT/GB									
2		WO	97/	3	7	6	4	5	10/16/97	PCT/US									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
2		Pierre Hainaut et al.; "Redox Modulation of p53 Conformation and Sequence-specific DNA Binding in vitro"; <i>Cancer Research</i> vol. 35, No. 18, pp. 4469-4473, (1993)																	
2		James J. Ryan et al., "Alteration of p53 Conformation and Induction of Adoptosis in a Murine Erythroleukemia Cell Line By Dimethylsulfoxide"; <i>Leukemia Research</i> , vol. 18, No. 8, pp. 612-621; (1994)																	
2		C. Randell Brown, et al., "Correcting Temperature-sensitive Protein Folding Defects"; <i>J.Clin. Investigations</i> ; Vol. 99 No. 6, pp 1432-1444, (1997)																	
2		P.V.M. Shekhar, et al., "Altered P53 conformation: A novel mechanism of wild-type p53 functional inactivation in a model for early human breast cancer"; <i>International Journal of Oncology</i> , vol. 11, No. 5, pp. 1087-1094, (1997)																	
2		Pierre Hainut, et al., "A Structural Role for Metal Ions in the "Wild-type" Conformatin of the Tumor Suppressor Protein p53"; <i>Cancer Research</i> , vol. 53, no. 8 pp. 1739-1742, (1993)																	
2		Blagoskonny, et al., "Geldanamycin selectivity destabilizes mutant p53" <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , vol. 36, page 429, 1995, Abstract 2558																	
2		Hiroshi Sakagami et al., "Induction of DNA Fragmentation in Human Myelogenous Leukaemic Cell Lines by Phenothiazine-Related Compounds"; <i>Anticancer Research</i> 15 pp.2533-40 (1995)																	
2		Mark A. Wuonola, et al., "The Primary in Vitro Antitumor Screening of "Half-Mustard Type" Phenothiazines"; <i>Anticancer Research</i> , 17 pp. 3409-3423, (1997)																	
2		Sylvia Nagy, et al., "Antitumor Activity of Phenothiazine-Related Compounds" <i>Anticancer Research</i> 16, pp. 1915-1918, (1996)																	
2		Noboru Motohashi, et al., "Synthesis and Antitumor Activity of 1-[2-(Chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)]alkyl-1-Ureas as Potent Anticancer Agents"; <i>Anticancer Research</i> , vol. 16, pp. 2525-2532 (1996)																	
2		Marek Gniazdowsky, et al., "Thiol-Dependent Inhibition of RNA Synthesis in vitro By Acridines, Structure-Inhibition Relationships, <i>Cancer Letters</i> , 15, pp. 73-79 (1982)																	

U.S. PAT. 09/863,976
 05/23/01

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10228B	SERIAL NO. Express Mail No. EL446402284US
		APPLICANT Farzan Rastinejad et al.	04/863, 976
		FILING DATE May 23, 2001	GROUP 1624 (anticipated)


	William Wilson, et al., "Hypoxia-Selective Antitumor Agents. 2. Electronic Effects of 4-Substituents on the Mechanisms of Cytotoxicity and Metabolic Stability of Nitracrine Derivatives"; <i>J. Med. Chem.</i> , vol. 32, pp. 31-38 (1989)
	T.R. Hupp, "Regulation of p53 Protein Function Through Alternations In Protein-Folding Pathways", <i>Cell. Mol. Life Sci.</i> , vol. 55 pp. 88-95 (1999)
	K. Sakagami et al., Chemical Abstracts, vol. 24, No. 25, June 17, 1996, Abstract No. 332043
	M. Wuonola et al., Chemical Abstracts, vol. 128, 1998, Abstract No. 175800
	M. Wuonola et al., Chemical Abstracts, vol. 128, No. 14, April 6, 1998, Abstract No. 162631
	T. Ohnishi, et al., "Restoration of Mutant TP53 to Normal TP53 Function by Glycerol as a Chemical Chaperone", <i>Radiation Research</i> , vol. 151, no. 4 pp. 498-500 (1999)

EXAMINER 	DATE CONSIDERED 9/17/02
------------------------------------------------------------------------------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION (See several sheets if necessary)		ATTY. DOCKET NO. PC10228B		SERIAL NO. 09/863,976	
		APPLICANT Farzan Rastinejad et al.			
		FILING DATE May 23 2001		GROUP 1614	
MAY 15 2002 U.S. PATENT DOCUMENTS					
EXAMINER INITIAL & TRADE		DOCUMENT NUMBER	DATE	NAME	CLASS SUBCLASS FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER			DATE	COUNTRY	CLASS SUBCLASS TRANSLATION YES NO
		WO 02/ 2 4 6 9 2	3/28/02	PCT	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
9		M. Hollstein et al., "Database of p53 gene somatic mutations in human tumors and cell lines", Nucleic Acids Research, vol. 22, p. 3551-3555, (1994)			
A		P.M. O'Connor et al., "Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth Inhibitory Potency of 123 Anticancer Agents", Cancer Research, vol. 57, p. 4285-4300 (1997)			
A		A. N. Bullock et al., "Rescuing The Function of Mutant p53", Nature Reviews, vol. 1, pp. 68-76, (2001)			
1		Martin L. Smith et al., "Chemotherapeutic Targeting of p53", Cancer Biology & Therapy, Internet pre-published on Sept. 5, 2001 as Manuscript MS # 08-30-02			
2		Jackson B. Gibbs, "Mechanism-Based Target Identification and Drug Discovery in Cancer Research", Science Magazine, vol. 287, pp. 1969-1973 (2000)			
0		Elizabeth Pennisi, "Bracing p53 for the War on Cancer", Science Magazine, vol. 286, p. 2431 (1999)			
D		Rishu Takimoto et al., "The Mutant p53 Conformation Modifying Drug, CP-31398, Can Induce Apoptosis of Human Cancer Cells and can Stabilize Wild-Type p53 Protein", Cancer Biology & Therapy, Internet pre-published on September 4, 2001 as Manuscript MS# 08-08-01			
Q		Barbara A. Foster et al., Science Magazine, "Pharmacological Rescue of Mutant p53 Conformation and Function", vol. 286, pp.2507-2510 (1999)			
Q		Craig Caldwell et al., "The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth", Gene, vol. 277 pp. 15-30 (2001)			
Q		The Journal of Antibiotics, Lucilactaene, a New Cell Cycle Inhibitor in p53-Transfected Cancer Cells", vol. 54, pp. 850-854 (2001)			
Q		Jun-Li Luo, et al "U1-induced DNA Damage and Mutations in Hupki (Human p53 Knock-in) Mice Recaptulate p53 Hotspot Alterations in Sun-exposed Human Skin", Cancer Research, vol. 61, pp. 8158-8163 (2001)			
Q		Foster et al. Science (1999), 286 (5449), 2507-2510 Abstract Only			
EXAMINER: 		DATE CONSIDERED			

 COPY OF PAPERS
 ORIGINALLY FILED

9/17/02
RECEIVED
 MAY 20 2002
 TECH CENTER 1600-2300